A novel chromatin regulator signature predicts the prognosis, clinical features and immunotherapy of colon cancer

References

• Sung H , FerlayJ , SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Xi Y , XuP. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol.14(10), 101174 (2021).
   PubMed Web of Science ®Google Scholar
• Biller LH , SchragD. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA325(7), 669–685 (2021).
   PubMed Web of Science ®Google Scholar
• Singh MP , RaiS , PandeyA , SinghNK , SrivastavaS. Molecular subtypes of colorectal cancer: an emerging therapeutic opportunity for personalized medicine. Genes Dis.8(2), 133–145 (2021).
   PubMed Web of Science ®Google Scholar
• Ahluwalia P , MondalAK , BloomerCet al. Identification and clinical validation of a novel 4 gene-signature with prognostic utility in colorectal cancer. Int. J. Mol. Sci.20(15), 3818–3836 (2019).
   PubMed Web of Science ®Google Scholar
• Dai S , XuS , YeY , DingK. Identification of an immune-related gene signature to improve prognosis prediction in colorectal cancer patients. Front. Genet.11, 607009 (2020).
   PubMed Web of Science ®Google Scholar
• Li M , WangH , LiWet al. Identification and validation of an immune prognostic signature in colorectal cancer. Int. Immunopharmacol.88, 106868 (2020).
   PubMed Web of Science ®Google Scholar
• Liu Z , LuT , WangYet al. Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. J. Cell Mol. Med.25(14), 6874–6886 (2021).
   PubMed Web of Science ®Google Scholar
• Lu Y , WangW , LiuZ , MaJ , ZhouX , FuW. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer. Mol. Med.27(1), 83 (2021).
   PubMed Web of Science ®Google Scholar
• Zhu K , LiuX , DengW , WangG , FuB. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer. Hereditas159(1), 13 (2022).
   PubMed Web of Science ®Google Scholar
• Lu J , XuJ , LiJet al. FACER: comprehensive molecular and functional characterization of epigenetic chromatin regulators. Nucleic Acids Res.46(19), 10019–10033 (2018).
   PubMed Web of Science ®Google Scholar
• Plass C , PfisterSM , LindrothAM , BogatyrovaO , ClausR , LichterP. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet.14(11), 765–780 (2013).
   PubMed Web of Science ®Google Scholar
• Marazzi I , GreenbaumBD , LowDHP , GuccioneE. Chromatin dependencies in cancer and inflammation. Nat. Rev. Mol. Cell Biol.19(4), 245–261 (2018).
   PubMed Web of Science ®Google Scholar
• Chen H , LiZ , WuFet al. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. IUBMB Life1–18 (2021).
   Web of Science ®Google Scholar
• Ji G , ZhouW , DuJet al. PCGF1 promotes epigenetic activation of stemness markers and colorectal cancer stem cell enrichment. Cell Death Dis.12(7), 633–645 (2021).
   PubMed Web of Science ®Google Scholar
• Kuo S-H , YangS-H , WeiM-Fet al. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling. Cancer Cell Int.21(1), 436 (2021).
   PubMed Web of Science ®Google Scholar
• Nagano-Matsuo A , InoueS , KoshinoAet al. PBK expression predicts favorable survival in colorectal cancer patients. Virchows Arch.479(2), 277–284 (2021).
   PubMed Web of Science ®Google Scholar
• Yang Z-Y , YinS-P , RenQet al. BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion. Breast Cancer29(3), 516–530 (2022).
   PubMed Web of Science ®Google Scholar
• Smith JJ , DeaneNG , WuFet al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology138(3), 958–968 (2010).
   PubMed Web of Science ®Google Scholar
• Marisa L , DeReyniès A , DuvalAet al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLOS Med.10(5), e1001453 (2013).
   PubMed Web of Science ®Google Scholar
• Wu J , ZhangH , LiLet al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun. (Lond.)40(7), 301–312 (2020).
   PubMed Web of Science ®Google Scholar
• Cao S , LiJ , ZhangJ , LiH. Development and validation of a prognostic nomogram for predicting the overall survival of myxofibrosarcoma patients: a large population-based study. Transl. Cancer Res.10, 923–937 (2021).
   PubMed Web of Science ®Google Scholar
• Sturm G , FinotelloF , PetitprezFet al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics35(14), i436–i445 (2019).
   PubMed Web of Science ®Google Scholar
• Newman AM , LiuCL , GreenMRet al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods12(5), 453–457 (2015).
   PubMed Web of Science ®Google Scholar
• Cao S , LiuH , FanJet al. An oxidative stress-related gene pair (/), competitive endogenous RNAs, and immune-infiltration patterns potentially regulate intervertebral disc degeneration development. Front. Immunol.12, 765382 (2021).
   PubMed Web of Science ®Google Scholar
• Danilova L , HoWJ , ZhuQet al. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol. Res.7(6), 886–895 (2019).
   PubMed Web of Science ®Google Scholar
• Li T , FanJ , WangBet al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune Cells. Cancer Res.77(21), e108–e110 (2017).
   PubMed Web of Science ®Google Scholar
• Yoo M , ShinJ , KimJet al. DSigDB: drug signatures database for gene set analysis. Bioinformatics31(18), 3069–3071 (2015).
   PubMed Web of Science ®Google Scholar
• Geeleher P , CoxN , HuangRS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLOS ONE9(9), e107468 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang J-X , SongW , ChenZ-Het al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol.14(13), 1295–1306 (2013).
   PubMed Web of Science ®Google Scholar
• Liu S , CaoQ , AnG , YanB , LeiL. Identification of the 3-lncRNA signature as a prognostic biomarker for colorectal cancer. Int. J. Mol. Sci.21(24), 9359–9376 (2020).
   PubMed Web of Science ®Google Scholar
• Song K , CaiH , ZhengHet al. Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer. Brief Bioinform.22(5), 1–15 (2021).
   PubMed Web of Science ®Google Scholar
• Wang S-Y , GaoK , DengD-Let al. TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway. Oncotarget7(3), 2878–2888 (2016).
   PubMedGoogle Scholar
• Popat S , HubnerR , HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Roth AD , DelorenziM , TejparSet al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl Cancer Inst.104(21), 1635–1646 (2012).
   PubMedGoogle Scholar
• Wang C , XuK , DengFet al. A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer. Transl. Cancer Res.10(5), 2229–2246 (2021).
   PubMed Web of Science ®Google Scholar
• Bagchi A , PapazogluC , WuYet al. CHD5 is a tumor suppressor at human 1p36. Cell128(3), 459–475 (2007).
   PubMed Web of Science ®Google Scholar
• Kolla V , ZhuangT , HigashiM , NaraparajuK , BrodeurGM. Role of CHD5 in human cancers: 10 years later. Cancer Res.74(3), 652–658 (2014).
   PubMed Web of Science ®Google Scholar
• Baykara O , TansarikayaM , BulutP , DemirkayaA , BuyruN. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC). Gene618, 65–68 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao R , YanQ , LvJet al. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer76(3), 324–331 (2012).
   PubMed Web of Science ®Google Scholar
• Hall WA , PetrovaAV , ColbertLEet al. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Oncogene33(47), 5450–5456 (2014).
   PubMed Web of Science ®Google Scholar
• Wu X , ZhuZ , LiWet al. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res.14(3), R73 (2012).
   PubMed Web of Science ®Google Scholar
• Fatemi M , PaulTA , BrodeurGM , ShokraniB , BrimH , AshktorabH. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer120(2), 172–180 (2014).
   PubMed Web of Science ®Google Scholar
• Cai C , AshktorabH , PangXet al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLOS ONE7(1), e29750 (2012).
   PubMed Web of Science ®Google Scholar
• Wang L , HeS , TuYet al. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma. J. Clin. Neurosci.20(7), 958–963 (2013).
   PubMed Web of Science ®Google Scholar
• Liu JB , ZhouQB , XuJZ , WangGX , YuanWT. Influence of colorectal cancer tumor suppressor gene CHD5 methylation on its clinical and pathological characteristics. J. Biol. Regul. Homeost. Agents29(4), 889–893 (2015).
   PubMed Web of Science ®Google Scholar
• Zhao R , WangN , HuangH , MaW , YanQ. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma. Liver Int.34(6), e151–e160 (2014).
   PubMed Web of Science ®Google Scholar
• Jiang M , WangH , ChenH , HanY. SMARCD3 is a potential prognostic marker and therapeutic target in CAFs. Aging (Albany NY)12(20), 20835–20861 (2020).
   PubMedGoogle Scholar
• Tropée R , DeLa Peña Avalos B , GoughM , SnellC , DuijfPHG , DrayE. The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer. Breast Cancer Res. Treat.185(3), 601–614 (2021).
   PubMed Web of Science ®Google Scholar
• Babel I , BarderasR , Díaz-UriarteR , Martínez-TorrecuadradaJL , Sánchez-CarbayoM , CasalJI. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell Proteomics8(10), 2382–2395 (2009).
   PubMed Web of Science ®Google Scholar
• Barderas R , BabelI , Díaz-UriarteRet al. An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. J. Proteomics75(15), 4647–4655 (2012).
   PubMed Web of Science ®Google Scholar
• Saleh R , TahaRZ , ToorSMet al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol. Immunother.69(10), 1989–1999 (2020).
   PubMed Web of Science ®Google Scholar
• Fraschilla I , JeffreyKL. The speckled protein (SP) family: immunity’s chromatin readers. Trends Immunol.41(7), 572–585 (2020).
   PubMed Web of Science ®Google Scholar
• Xie N , YaoY , WanL , ZhuT , LiuL , YuanJ. Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Exp. Ther. Med.14(1), 338–343 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu X , LiaoY , TangL. Targeting BRD9 for cancer treatment: a new strategy. OncoTargets Ther13, 13191–13200 (2020).
   PubMed Web of Science ®Google Scholar
• Sun W , ZhangY , WongKCet al. Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. Hepatology67(6), 2302–2319 (2018).
   PubMed Web of Science ®Google Scholar
• Koshino A , NaganoA , OtaAet al. PBK enhances cellular proliferation with histone H3 phosphorylation and suppresses migration and invasion with CDH1 stabilization in colorectal cancer. Front. Pharmacol.12, 772926 (2021).
   PubMed Web of Science ®Google Scholar
• Jiang P , GuS , PanDet al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med.24(10), 1550–1558 (2018).
   PubMed Web of Science ®Google Scholar
• Hoey T . Drug resistance, epigenetics, and tumor cell heterogeneity. Sci. Transl. Med.2(28), 28ps19 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma SV , LeeDY , LiBet al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell141(1), 69–80 (2010).
   PubMed Web of Science ®Google Scholar